Skip to main content
. 2019 May 30;8:e46551. doi: 10.7554/eLife.46551

Figure 3. Anti-NRG1 significantly inhibits the tumor growth in vivo of SCCs that express both NRG1 and ERBB3.

Effect of anti-NRG1 or anti-Ragweed (control) antibodies in (A) FaDu (head and neck), HCC95 (lung) and KYSE-180 (esophagus) SCC cell lines in preclinical mouse xenograft models, N = 8–12 mice/group, (B) Lung SCC PDX models, n = 4 mice/group, and (C) Lgr5CreERT2; Ptenflox/flox; KrasLSL-G12D/+ skin GEMM, n = 7–8 mice/group. Statistical significance was determined by Log-rank test. Red arrow indicates the time of the final antibody dose. (D) H and E staining for GEMM skin at the end of study.

Figure 3.

Figure 3—figure supplement 1. Anti-NRG1 inhibits in vivo tumor growth in SCC models.

Figure 3—figure supplement 1.

Effect of anti-NRG1 or anti-Ragweed (control) antibodies in FaDu (head and neck), HCC95 (lung) and KYSE-180 (esophagus) SCC cell lines in preclinical mouse xenograft models, N = 8–12 mice/group. LUN#120, LUN#150 and LUN#331 are lung SCC PDX models, n = 4 mice/group. Percent change in tumor volume was determined at after one weak from last antibody dose in Figure 3 with respect to initial tumor volume of respective animals.
Figure 3—figure supplement 2. Anti-NRG1 does not inhibit the growth of ovarian models expressing NRG1 and ERBB3 receptor in vivo.

Figure 3—figure supplement 2.

(A) In vitro growth of ovarian cell lines in the presence of anti-NRG1 or anti-Ragweed (control) antibody. Expression of NRG1, Erbb3, Erbb4 and TP63 by RNAseq are shown below the respective in vitro growth of different cell lines. Average growth is presented as is mean with standard error of mean relative to anti-Ragweed from four independent experiments with more than three replicates in every experiment. Statistical significance was determined using t-test with * indicates p<0.05. (B) Efficacy of anti-NRG1 or anti-Ragweed (control) antibody in ovarian PDX models, n = 8–12 mice/group. Red arrow indicates the last dose of antibody.